Aug 10, 2023
Vancouver, WA (Aug 10, 2023) — Absci Corporation (Nasdaq: ABSI), a generative AI drug creation
company, today announced that leading researchers at the California Institute of Technology (Caltech)
in conjunction with Absci, a leader in AI drug creation, received a grant from the Bill & Melinda Gates
Foundation.The grant supports the joint effort of Caltech and Absci to discover affordable HIV
therapeutic vaccinations, with the goal of making a significant step forward in the fight against the global
HIV/AIDS epidemic.
The collaboration between Caltech and Absci, led by Dr. Pamela Bjorkman, brings together
cutting-edge research capabilities and advanced technological expertise in structural biology and
immunology, protein design, synthetic biology, and generative AI. By leveraging their combined
strengths, the teams will work to develop a novel HIV therapy that first exposes and then binds to a
highly conserved epitope binding site on HIV-1 to potentially both treat and protect against infection
from all strains of the virus.
More than 40 years after the AIDS pandemic began, there is no vaccine or cure for HIV. Antiretroviral
therapies (ARTs) help many people live longer, healthier lives, but they do not completely eliminate the
virus and must be taken for life. Additionally, the cost and inaccessibility of these drugs
disproportionately affect millions of people from low-income and marginalized communities. This new
partnership between Caltech and Absci, facilitated by the generous grant from the Gates Foundation,
aims to address this disparity by focusing on the affordability, scalability, and accessibility of HIV
therapeutic vaccinations. Combining the latest advances and expertise across their respective fields,
Caltech and Absci aim to confront a challenge facing millions worldwide.
“We are thrilled to receive this grant from the Bill & Melinda Gates Foundation,” said Dr. Stephen Mayo,
Bren Professor of Biology and Chemistry and Merkin Institute Professor at Caltech and project
co-leader. “We’re committed to making transformative contributions to society through research and
innovation, and we are excited to partner with Absci, who has developed a powerful de novo AI
antibody platform that is helping to unlock new therapeutic possibilities. This collaboration with Absci
allows us to combine our expertise and work towards a common goal of developing affordable HIV
therapeutic vaccinations that can save lives and bring hope to millions.”
“We are honored to be partnering with Caltech on this critical project,” stated Sean McClain, Founder
and CEO of Absci. “At Absci, we are driven to transform lives through the power of generative AI and
synthetic biology. By joining forces with Dr. Pamela Bjorkman and Dr. Stephen Mayo, and with support
from the Gates Foundation,, we believe we can make significant strides towards developing affordable
HIV therapeutic vaccinations and positively impacting global health.”
About Absci
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to
create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential
to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple
drug characteristics important to both development and therapeutic benefit. With the data to learn, the
AI to create, and the wet lab to validate, Absci can screen billions of cells per week, allowing it to go
from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s vision is to
deliver breakthrough therapeutics at the click of a button, for everyone. Absci’s headquarters is in
Vancouver, WA, its AI Research Lab is in New York City, and its Innovation Center is in Zug,
Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), Twitter (@Abscibio), and
YouTube.
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our
website (www.absci.com) and our investor relations website (investors.absci.com), including without
limitation, through the posting of investor presentations, SEC filings, press releases, public conference
calls and webcasts on these websites, as well as on Twitter, LinkedIn, and YouTube. The information we
post on these websites and social media outlets could be deemed material. As a result, investors, the
media, and others interested in Absci are encouraged to review this information regularly. The contents
of our website and social media postings, or any other website that may be accessed from our website
or social media postings, shall not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended.
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,”
“pursues,” “anticipates,” “plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,” “extends,”
“expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including
statements regarding technology development efforts and the application of those efforts, including
acceleration of drug development timelines, reducing the time and costs related to drug development,
improving clinical and patient outcomes, advancements toward in silico drug design, drug discovery
and development activities, and the effective incorporation of our technology in drug design, and
research and technology development collaboration efforts, to be covered by the safe harbor provisions
for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. We make this statement to comply with those safe harbor provisions. These
forward-looking statements reflect our current views about our plans, intentions, expectations,
strategies, and prospects, which are based on the information currently available to us and on
assumptions we have made. We can give no assurance that the plans, intentions, expectations, or
strategies will be attained or achieved. Furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by a variety of risks and factors that are
beyond our control, including, without limitation, risks and uncertainties relating to our ability to
effectively collaborate on research, drug discovery and development activities with our partners or
potential partners; along with those risks set forth in our most recent periodic report filed with the U.S.
Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other
important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except
as required by law, we assume no obligation to update publicly any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Absci Media Contact
press@absci.com
Absci Investor Contact
investors@absci.com